Halozyme Therapeutics (HALO) Tops Q1 EPS by 5c, Revenues Beat; Offers FY21 EPS Mid-Point Guidance Above Consensus, FY21 Revs. Mid-Point Views Below Consensus
Go back to Halozyme Therapeutics (HALO) Tops Q1 EPS by 5c, Revenues Beat; Offers FY21 EPS Mid-Point Guidance Above Consensus, FY21 Revs. Mid-Point Views Below Consensus| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 115.13 +3.68 (3.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $111.45 | 52 Week High | $18.39 | |||
| Open | $111.50 | 52 Week Low | $6.96 | |||
| Day High | $115.18 | P/E | N/A | |||
| Day Low | $110.95 | EPS | $-0.58 | |||
| Volume | 4,151,274 | |||||
